3 October 2023 in F&S Science
1 September 2017 in Fertility and Sterility
Objective Previous research has demonstrated no difference in live-birth rate in infertile women with polycystic ovary syndrome (PCOS) when comparing those using clomiphene citrate (CC) and metformin to matched controls using CC alone. Because letrozole (LE) is associated with higher live-birth and ovulation rates in PCOS patients, it has become the first line of treatment for this patient population. The aim of this study is to investigate if the addition of metformin improves follicular recruitment and pregnancy rates in ovulation induction cycles with intrauterine insemination (OI/IUI) in infertile PCOS women using LE. Design Retrospective chart review Materials and Methods All OI/IUI cycles from January 2012 to August 2016 utilizing letrozole treatment were reviewed. A total of 268 OI/IUI cycles with a diagnosis of PCOS were included. Demographics (age, body mass index (BMI)), LE dose, metformin use, number of mature follicles, size of lead follicle and pregnancy outcomes were collected. Results were compared based on whether the patient was taking letrozole and metformin (LE-M) versus letrozole only (LE). Graphpad Prism 6.0 was used to analyze the data. Descriptive data was analyzed as percentages and means with standard deviations. Statistical differences between groups were determined using Fisher’s exact and chi-square with a p-value <0.05 considered significant. Results A total of 268 OI/IUI cycles were analyzed, of which 159 received LE-M and 109 received LE. There were no significant differences in age, AMH or BMI when comparing the two groups. There were no statistical differences in follicular recruitment (1.5 + 0.8 versus 1.6 + 0.8, p=0.8939) or pregnancy rates (10% versus 13%, p=0.5663) when comparing the LE-M versus LE groups, respectively. Conclusions The addition of metformin to LE does not improve follicular recruitment or pregnancy rates in OI/IUI cycles in infertile PCOS women.
1 September 2020 in Fertility and Sterility
30 August 2024 in F&S Reviews
9 January 2025 in F&S Reports
To evaluate the effect of educational videos on the utilization of preconception genetic carrier screening in patients with infertility. Survey study. New patients presenting for infertility consult with one of five providers (4 physicians and 1 nurse practitioner) from November 2021 through February 2022. Patients were assigned to the web application EngagedMD video arm or in-person counseling arm for education on preconception genetic screening. The primary study outcome was completion of genetic carrier screening. The secondary outcomes were provider rating of patient comprehension and provider-rated time demand of counseling. A total of 73 patients were enrolled: 42 in the video arm and 31 in the in-person counseling arm. The survey response rate was 100% for patients and providers. Patients assigned to the video counseling arm were significantly more likely to plan to proceed with carrier screening (78.6%) than those receiving only in-office counseling (41.9%). The odds ratio associating video arm with actual completion of screening was 5.07 (95% confidence interval, 1.84–13.96). Patients who completed EngagedMD videos were perceived by providers to have a noninferior understanding of the purpose of carrier screening compared with those who underwent standard counseling, assessed via “teach-back” method. Providers also rated that multimedia education use significantly decreased demand on appointment time. The use of patient education videos increases utilization of preconception genetic carrier screening and is an acceptable alternative to in-person provider counseling.
19 December 2025 in North American Proceedings in Gynecology & Obstetrics
Background: Early pregnancy loss is a very common experience resulting in adverse mental health outcomes, such as depression and PTSD. There is currently little research on the impact of parental leave on improving these mental health outcomes. As more employment policies are beginning to provide parental leave for early pregnancy loss, the efficacy of this treatment must be explored. Objective: This study aimed to investigate the impact of parental leave after early pregnancy loss on mental health and access to professional mental health support. Study Design: A 2023 retrospective cohort online survey was created after screening and recruiting participants via electronic medical records. To be eligible, participants had to be 18 years of age and above diagnosed with first trimester pregnancy loss in 2022, English speaking, and in Cincinnati, OH. Results: Of the eligible 297 patients, 65 (21.9%) usable responses were collected. The rate of leave among respondents was 15.4% (n=10) which is similar to a national rate of 21.9% of companies offering leave (p=0.366). Those that took leave had significantly lower modified PHQ scores out of 9 (3.5 +/- 2.12) than those that didn’t (5.35 +/- 2.55) (p=0.035). The relative risk of patients believing their mental health was better due to leave was 33.45 (CI: 4.72-236.89, p<0.001). Patients that took leave also believed that they were better able to access professional mental health support (p<0.001), although only 50% of those actually did proceed with therapy. Conclusion: Taking leave after early pregnancy loss results in less depressive symptoms and a more positive view of mental health and support access. Future studies should continue to explore the impact of leave after loss and advocate for parental rights.